Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
KOD
$27.98
$
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Next Earnings
2026-02-25
Beta
2.649
Average Volume
Market Cap
Last Dividend
CIK
0001468748
ISIN
US50015M1099
CUSIP
50015M109
CEO
Victor Perlroth
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
109
IPO Date
2018-10-04
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Kodiak Sciences Stock Up 480% as One Fund Discloses $53 Million Buy | Baker Bros. Advisors increased its Kodiak Sciences stake by 2,608,696 shares; the estimated trade size was $53.42 million. | The Motley Fool | 2026-02-23 13:20:26 |
| Kodiak Sciences (NASDAQ:KOD) Shares Down 5.9% – What’s Next? | Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report)'s stock price dropped 5.9% on Friday. The stock traded as low as $25.32 and last traded at $25.1010. Approximately 60,109 shares changed hands during trading, a decline of 92% from the average daily volume of 725,091 shares. The stock had previously closed at $26.67. Analyst Upgrades | Defense World | 2026-02-22 04:36:56 |
| Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead | Connecticut-based Braidwell bought 2,072,788 shares in Kodiak Sciences in the fourth quarter. The quarter-end position value increased by $57.96 million, reflecting the establishment of the new position. | The Motley Fool | 2026-02-19 17:14:01 |
| Abbott Laboratories: A Key Reduction in Robert Bruce's Portfolio | Exploring the Strategic Moves of a Seasoned Value Investor Robert Bruce (Trades, Portfolio) recently submitted the 13F filing for the fourth quarter of 2025, p | GuruFocus | 2026-02-13 18:01:00 |
| KOD Stock Up 24% in 3 Months: Here's What You Need to Know | Kodiak Sciences' shares jump 24% in three months as late-stage retinal programs advance and fresh funding extends its cash runway, fueling investor confidence. | Zacks Investment Research | 2026-02-06 12:35:23 |
| Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026 | PALO ALTO, Calif., Feb. 4, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today participation at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) annual meeting on February 7, 2026. | PRNewsWire | 2026-02-04 07:00:00 |
| Kodiak Sciences Inc. (NASDAQ:KOD) Receives $26.57 Average PT from Brokerages | Shares of Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have given a buy recommendation | Defense World | 2026-01-14 03:52:48 |
| Kodiak Sciences Inc. (KOD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript | Kodiak Sciences Inc. (KOD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript | Seeking Alpha | 2026-01-12 20:45:58 |
| Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference | PALO ALTO, Calif., Jan. 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that senior management will present at the 44th Annual J.P. | PRNewsWire | 2026-01-07 20:19:00 |
| Kodiak Sciences (NASDAQ:KOD) Shares Down 5.8% – What’s Next? | Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report) shares traded down 5.8% during mid-day trading on Friday. The stock traded as low as $29.27 and last traded at $29.2750. 145,497 shares changed hands during trading, a decline of 76% from the average session volume of 603,202 shares. The stock had previously closed at $31.08. | Defense World | 2025-12-28 02:36:50 |
| Kodiak Sciences (NASDAQ:KOD) Hits New 12-Month High – Here’s What Happened | Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday. The company traded as high as $29.49 and last traded at $28.61, with a volume of 1282200 shares changing hands. The stock had previously closed at $26.00. Analysts Set New Price Targets Several equities research | Defense World | 2025-12-25 04:37:06 |
| Kodiak Sciences (NASDAQ:KOD) Shares Gap Up Following Insider Buying Activity | Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report) shares gapped up prior to trading on Monday after an insider bought additional shares in the company. The stock had previously closed at $26.00, but opened at $27.95. Kodiak Sciences shares last traded at $28.2410, with a volume of 141,605 shares. Specifically, Director Bros. Advisors Lp Baker | Defense World | 2025-12-23 01:16:56 |
| What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 | IONS, GPCR, MNPR and KOD more than double in 2025 as policy clarity, M&A revival and clinical wins lift biotech momentum into 2026. | Zacks Investment Research | 2025-12-22 11:16:08 |
| Bros. Advisors Lp Baker Acquires 2,608,696 Shares of Kodiak Sciences (NASDAQ:KOD) Stock | Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report) Director Bros. Advisors Lp Baker acquired 2,608,696 shares of the firm's stock in a transaction dated Thursday, December 18th. The stock was bought at an average price of $23.00 per share, with a total value of $60,000,008.00. Following the purchase, the director directly owned 18,358,772 shares in | Defense World | 2025-12-21 04:02:48 |
| Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares | PALO ALTO, Calif. , Dec. 18, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced the closing of its previously announced underwritten public offering of 8,000,000 shares of its common stock, which includes 1,043,478 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a price to the public of $23.00 per share. | PRNewsWire | 2025-12-18 20:26:00 |
| Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock | PALO ALTO, Calif. , Dec. 16, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced the pricing of an upsized underwritten public offering of 6,956,522 shares of its common stock at a price to the public of $23.00 per share. | PRNewsWire | 2025-12-16 22:55:00 |
| Kodiak Sciences Announces Proposed Public Offering of Common Stock | PALO ALTO, Calif. , Dec. 15, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that it has commenced an underwritten public offering of 6,000,000 of shares of its common stock. | PRNewsWire | 2025-12-15 16:01:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| 5 | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13D/A | 2025-12-19 | 2025-12-19 | View Filing |
| 4 | 2025-12-19 | 2025-12-19 | View Filing |
| 8-K | 2025-12-18 | 2025-12-18 | View Filing |
| 424B5 | 2025-12-17 | 2025-12-17 | View Filing |
| 424B5 | 2025-12-15 | 2025-12-15 | View Filing |
| 10-Q | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K | 2025-11-13 | 2025-11-13 | View Filing |
| SC 13G | 2025-08-19 | 2025-08-19 | View Filing |
| 10-Q | 2025-08-13 | 2025-08-13 | View Filing |
| 8-K | 2025-08-13 | 2025-08-13 | View Filing |
| 4 | 2025-07-08 | 2025-07-08 | View Filing |
| 4 | 2025-07-08 | 2025-07-08 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 4 | 2025-06-17 | 2025-06-17 | View Filing |
| 8-K | 2025-06-03 | 2025-06-03 | View Filing |
| 10-Q | 2025-05-14 | 2025-05-14 | View Filing |
| 8-K | 2025-05-14 | 2025-05-14 | View Filing |
| SC 13G/A | 2025-04-29 | 2025-04-29 | View Filing |
| ARS | 2025-04-22 | 2025-04-22 | View Filing |
| DEFA14A | 2025-04-22 | 2025-04-22 | View Filing |
| DEF 14A | 2025-04-22 | 2025-04-22 | View Filing |
| S-8 | 2025-03-27 | 2025-03-27 | View Filing |
| 10-K | 2025-03-27 | 2025-03-27 | View Filing |
| 8-K | 2025-03-27 | 2025-03-27 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| 10-Q | 2024-11-14 | 2024-11-14 | View Filing |
| 8-K | 2024-11-14 | 2024-11-14 | View Filing |
| 10-Q | 2024-08-14 | 2024-08-14 | View Filing |
| 8-K | 2024-08-14 | 2024-08-14 | View Filing |
| 4 | 2024-08-07 | 2024-08-07 | View Filing |
| 4 | 2024-08-07 | 2024-08-07 | View Filing |
| 4 | 2024-07-02 | 2024-07-02 | View Filing |
| 4 | 2024-07-01 | 2024-07-01 | View Filing |
| 4 | 2024-07-01 | 2024-07-01 | View Filing |
| 4 | 2024-07-01 | 2024-07-01 | View Filing |
| 4 | 2024-07-01 | 2024-07-01 | View Filing |
| 4 | 2024-07-01 | 2024-07-01 | View Filing |
| 4 | 2024-06-18 | 2024-06-18 | View Filing |
| 4 | 2024-06-13 | 2024-06-13 | View Filing |
| 8-K | 2024-06-06 | 2024-06-06 | View Filing |
| 10-Q | 2024-05-15 | 2024-05-15 | View Filing |
| 8-K | 2024-05-15 | 2024-05-15 | View Filing |
| ARS | 2024-04-23 | 2024-04-23 | View Filing |
| DEFA14A | 2024-04-23 | 2024-04-23 | View Filing |
| DEF 14A | 2024-04-23 | 2024-04-23 | View Filing |
| S-8 | 2024-03-28 | 2024-03-28 | View Filing |
| 10-K | 2024-03-28 | 2024-03-28 | View Filing |
| 8-K | 2024-03-28 | 2024-03-28 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Choppiness Index Strategy | 20.55% | 0.97 | 31 | 0.55 | 0.67 | 11.67 |
| Market Cycle | 14.53% | 1.52 | 7 | 0.66 | 0.6 | 5.23 |
| Quantum Inspired Strategy | 14.25% | 1.08 | 27 | 0.51 | 0.45 | 4.94 |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | x | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | x |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxx | xxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxx% | x | x | xxxx | xxxx | xxx |
| xxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxx |
| xxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxx |
| xxxxxxxxxxxxxxxx | x% | x | x | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |